ATE476966T1 - Feste dispersion mit schwer wasserlöslichem wirkstoff - Google Patents
Feste dispersion mit schwer wasserlöslichem wirkstoffInfo
- Publication number
- ATE476966T1 ATE476966T1 AT07825366T AT07825366T ATE476966T1 AT E476966 T1 ATE476966 T1 AT E476966T1 AT 07825366 T AT07825366 T AT 07825366T AT 07825366 T AT07825366 T AT 07825366T AT E476966 T1 ATE476966 T1 AT E476966T1
- Authority
- AT
- Austria
- Prior art keywords
- active ingredients
- water soluble
- solid dispersion
- poorly water
- soluble active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82972006P | 2006-10-17 | 2006-10-17 | |
| PCT/IB2007/003062 WO2008047201A2 (en) | 2006-10-17 | 2007-10-08 | Solid dispersion comprising a poorly water soluble drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE476966T1 true ATE476966T1 (de) | 2010-08-15 |
Family
ID=39048880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07825366T ATE476966T1 (de) | 2006-10-17 | 2007-10-08 | Feste dispersion mit schwer wasserlöslichem wirkstoff |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8372836B2 (de) |
| EP (1) | EP2101741B1 (de) |
| JP (1) | JP2008100997A (de) |
| AR (1) | AR063317A1 (de) |
| AT (1) | ATE476966T1 (de) |
| DE (1) | DE602007008470D1 (de) |
| TW (1) | TW200819148A (de) |
| WO (1) | WO2008047201A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8535716B2 (en) | 2004-04-01 | 2013-09-17 | Tsrl, Inc. | Methods and composition of extended delivery of water insoluble drugs |
| US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| CA2607780A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | Purine derivatives |
| US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| NZ596610A (en) * | 2009-05-27 | 2014-04-30 | Samyang Biopharmaceuticals | A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same |
| CN103037843A (zh) | 2010-06-23 | 2013-04-10 | 麦它波莱克斯股份有限公司 | 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物 |
| CN104364329B (zh) | 2012-04-11 | 2016-08-17 | 陶氏环球技术有限责任公司 | 包含有机稀释剂和纤维素醚的组合物 |
| ES2692644T3 (es) * | 2012-05-02 | 2018-12-04 | Capsugel Belgium Nv | Dispersiones acuosas de polímeros de liberación controlada y cubiertas y cápsulas para las mismas |
| KR102220604B1 (ko) | 2012-07-17 | 2021-03-02 | 다우 글로벌 테크놀로지스 엘엘씨 | 유기 액체 희석제 및 매우 낮은 점도의 셀룰로즈 에테르를 포함하는 조성물 |
| EP2874607B1 (de) | 2012-07-17 | 2017-05-31 | Dow Global Technologies LLC | Feste dispersion mit hochsubstituierter hydroxyalkyl-methylcellulose |
| JP6396333B2 (ja) * | 2013-02-12 | 2018-09-26 | ベンド・リサーチ・インコーポレーテッドＢｅｎｄ Ｒｅｓｅａｒｃｈ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 低水溶性活性物質の固体分散体 |
| US9737538B2 (en) * | 2013-02-12 | 2017-08-22 | Bend Research, Inc. | Solid dispersions of low-water solubility actives |
| EP4066841A1 (de) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon |
| CN105636594A (zh) | 2013-08-12 | 2016-06-01 | 托凯药业股份有限公司 | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 |
| WO2015047763A1 (en) | 2013-09-25 | 2015-04-02 | Dow Global Technologies Llc | Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose |
| MX2016007522A (es) | 2013-12-11 | 2017-12-15 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| WO2015095659A2 (en) * | 2013-12-20 | 2015-06-25 | Phosphorex, Inc. | Indirubin solid dispersion composition |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10245238B2 (en) | 2014-05-15 | 2019-04-02 | Theravalues Corporation | Composition for oral intake |
| US9782356B2 (en) | 2014-05-20 | 2017-10-10 | Dow Global Technologies Llc | Capsule shells comprising an esterified cellulose ether |
| DE102014012020A1 (de) * | 2014-08-13 | 2016-02-18 | Clariant International Ltd. | VOC-arme Amine als oberflächenaktiver Bestandteil in Dispersionen |
| WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| EP3226861A2 (de) * | 2014-12-05 | 2017-10-11 | Centre National de la Recherche Scientifique (CNRS) | Verbindungen zur behandlung von zystischer fibrose |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| WO2017040362A1 (en) * | 2015-09-03 | 2017-03-09 | Merck Sharp & Dohme Corp. | Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations |
| JP6971043B2 (ja) | 2016-03-04 | 2021-11-24 | 株式会社リコー | 微粒子の製造方法 |
| MX2018012557A (es) | 2016-04-15 | 2019-07-04 | Janssen Sciences Ireland Uc | Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside. |
| EP3642197A1 (de) * | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Heterozyklische kleinmolekülige modulatoren von menschenlichen sting |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| WO2019193488A1 (en) | 2018-04-06 | 2019-10-10 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| BR112021001170A2 (pt) | 2018-07-30 | 2021-04-27 | Chugai Seiyaku Kabushiki Kaisha | dispersão sólida de derivado de hidantoína |
| US20220287976A1 (en) | 2019-08-15 | 2022-09-15 | Capsugel Belgium Nv | Ammonia as a processing aid for sprayed solid dispersions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE400252T1 (de) * | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
| MXPA03011933A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados. |
| EP1404300B1 (de) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
| ES2310676T3 (es) * | 2002-12-20 | 2009-01-16 | Pfizer Products Inc. | Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa. |
| US8617604B2 (en) * | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
| CA2607780A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | Purine derivatives |
| WO2006129167A1 (en) * | 2005-05-31 | 2006-12-07 | Pfizer Products Inc. | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS |
| AU2007216247A1 (en) * | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
-
2007
- 2007-10-08 WO PCT/IB2007/003062 patent/WO2008047201A2/en active Application Filing
- 2007-10-08 AT AT07825366T patent/ATE476966T1/de not_active IP Right Cessation
- 2007-10-08 US US12/311,543 patent/US8372836B2/en active Active
- 2007-10-08 DE DE602007008470T patent/DE602007008470D1/de active Active
- 2007-10-08 EP EP07825366A patent/EP2101741B1/de active Active
- 2007-10-12 JP JP2007266713A patent/JP2008100997A/ja active Pending
- 2007-10-16 AR ARP070104580A patent/AR063317A1/es not_active Application Discontinuation
- 2007-10-16 TW TW096138648A patent/TW200819148A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200819148A (en) | 2008-05-01 |
| WO2008047201A2 (en) | 2008-04-24 |
| US8372836B2 (en) | 2013-02-12 |
| WO2008047201A3 (en) | 2008-06-26 |
| US20100029667A1 (en) | 2010-02-04 |
| AR063317A1 (es) | 2009-01-21 |
| EP2101741A2 (de) | 2009-09-23 |
| EP2101741B1 (de) | 2010-08-11 |
| DE602007008470D1 (en) | 2010-09-23 |
| JP2008100997A (ja) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE476966T1 (de) | Feste dispersion mit schwer wasserlöslichem wirkstoff | |
| BRPI0818874A2 (pt) | Liberação de agentes ativos | |
| BRPI0806918A2 (pt) | Agentes de alvejamento para substratos celulósicos | |
| ATE482618T1 (de) | Wirkstoffkombinationen | |
| BRPI0912615A2 (pt) | agonistas de receptor y2 e/ou y4 de longa ação | |
| ATE484194T1 (de) | Wirkstoffkombinationen | |
| BRPI0820819A2 (pt) | Formulação de anticorpos | |
| DE602007000878D1 (de) | Biodiesel-Kaltfiltrierverfahren | |
| BRPI0812753A2 (pt) | Combinações de substância ativas acaricidas | |
| BRPI0922730A2 (pt) | formulação de anticorpo | |
| FR2896094B1 (fr) | Structure de connecteur | |
| DE602007011880D1 (de) | Partikelmischgerät | |
| DE502007001779D1 (de) | Anhängekupplung | |
| BRPI0812228A2 (pt) | Combinações de substâncias ativas fungicidas | |
| BRPI0817974A2 (pt) | Combinações de substâncias ativas com propriedades inseticidas e acaricidas. | |
| BRPI0716049A2 (pt) | dispersÕes de nanourÉias, contendo substÂncias ativas | |
| DE602007010950D1 (de) | Dosierpumpe | |
| BRPI0820538A2 (pt) | Isoformas de neuregulina solúveis ativas modificadas pós-traducionalmente | |
| EE200800057A (et) | Antimikroobne ravimvorm | |
| BRPI0907524A2 (pt) | Formulação de microcápsula de malation estabilizadas | |
| ES1064046Y (es) | Multiventuri dosificador | |
| FR2918505B1 (fr) | Attenuateur coaxial | |
| ITFI20080186A1 (it) | Miscelatore msa 206 | |
| ES2388801B1 (es) | Laser de colorante en estado solido. | |
| ZA200808377B (en) | Active substance combinations with insecticidal properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |